You are here
Urge Incontinence Treatment Approved for Marketing in the European Union
CORONA, Calif., June 21 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. , a leading specialty pharmaceutical company, announced today that the European Union's Commission of the European Communities has granted marketing authorization to Watson's oxybutynin transdermal product for the symptomatic treatment of urge incontinence and/or increased urinary frequency and urgency as may occur in patients with unstable bladder.
Approval of the application, filed by Watson's wholly-owned European subsidiary, results in a single Marketing Authorization with unified labeling that is immediately valid in all 25 EU-Member States.
On September 24, 2003, Watson announced that it had entered into a marketing and supply agreement with UCB Pharma, pursuant to which UCB Pharma will market the oxybutynin transdermal product in Europe. UCB Pharma expects to launch the product in the fourth quarter 2004. Watson currently markets the product in the United States under the name OXYTROL®.
Source: Watson Pharmaceuticals, Inc.